Editing Clonidine (section)

=== Spasticity ===
Clonidine has some role in the treatment of spasticity caused by spinal cord injury, acting principally by inhibiting excessive sensory transmission{{clarify span|below the level of injury.|date=March 2024}} Its use, however, is mainly as a second or third line agent, due to side effects such as [[hypotension]], [[bradycardia]], and [[drowsiness]].<ref>{{cite journal | vauthors = Chang E, Ghosh N, Yanni D, Lee S, Alexandru D, Mozaffar T | title = A Review of Spasticity Treatments: Pharmacological and Interventional Approaches | journal = Critical Reviews in Physical and Rehabilitation Medicine | volume = 25 | issue = 1–2 | pages = 11–22 | date = 2013 | pmid = 25750484 | pmc = 4349402 | doi = 10.1615/CritRevPhysRehabilMed.2013007945 }}</ref> Clonidine can be administered [[intrathecal]]ly,<ref name="PMID18443642">{{cite journal | vauthors = Smith HS, Deer TR, Staats PS, Singh V, Sehgal N, Cordner H | title = Intrathecal drug delivery | journal = Pain Physician | volume = 11 | issue = 2 Suppl | pages = S89–S104 | date = March 2008 | doi = 10.36076/ppj.2008/11/S89 | pmid = 18443642 }}</ref> which confers various benefits, including a reduction or prevention of the blood pressure lowering effects and increased effectiveness against spasticity.<ref name="PMID11723871">{{cite journal | vauthors = Rémy-Néris O, Denys P, Bussel B | title = Intrathecal clonidine for controlling spastic hypertonia | journal = Physical Medicine and Rehabilitation Clinics of North America | volume = 12 | issue = 4 | pages = 939–51, ix | date = November 2001 | doi = 10.1016/S1047-9651(18)30040-8 | pmid = 11723871 }}</ref> The effectiveness of intrathecal clonidine is comparable to that of intrathecal baclofen for spasticity.<ref name=PMID11723871/>